VSTM: Verastem Inc. Stocks News on July 1, 2025

VSTM

MT Newswires

6 days ago

RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk

VSTM

MT Newswires

6 days ago

Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

VSTM

Business Wire

6 days ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

VSTM

Zacks

11 days ago

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

VSTM

Business Wire

a month ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

VSTM

Zacks

a month ago

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

VSTM

Business Wire

a month ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

US High Growth Tech Stocks to Watch in May 2025

VSTM

Simply Wall St.

a month ago

US High Growth Tech Stocks to Watch in May 2025

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

VSTM

TipRanks

a month ago

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

VSTM

MT Newswires

a month ago

Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

VSTM

Business Wire

a month ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus partners with Verastem for companion diagnostic development

VSTM

Medical Device Network

a month ago

Tempus partners with Verastem for companion diagnostic development

VSTM

MT Newswires

a month ago

Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

VSTM

Associated Press Finance

2 months ago

Verastem: Q1 Earnings Snapshot

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

VSTM

Business Wire

2 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

FDA grants accelerated approval to avutometinib, defactinib combination

VSTM

TipRanks

2 months ago

FDA grants accelerated approval to avutometinib, defactinib combination

VSTM

MT Newswires

2 months ago

B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating

VSTM

MT Newswires

2 months ago

Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating

VSTM

MT Newswires

2 months ago

RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

VSTM

Benzinga

2 months ago

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

VSTM

Business Wire

2 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

VSTM

MT Newswires

2 months ago

Verastem Receives US FDA Approval for Drug Combination to Treat Recurrent Ovarian Cancer

Verastem Oncology to Present at Upcoming Investor Conferences

VSTM

Business Wire

2 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

VSTM

MT Newswires

2 months ago

B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating

VSTM

MT Newswires

2 months ago

Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million

Verastem Oncology Announces $75 million Private Placement

VSTM

Business Wire

2 months ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

VSTM

Business Wire

2 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

VSTM

Zacks

2 months ago

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

VSTM

Zacks

2 months ago

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

VSTM

MT Newswires

3 months ago

Jefferies Initiates Verastem at Buy With $15 Price Target

VSTM

MT Newswires

3 months ago

Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

Business Wire

3 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

Zacks

3 months ago

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

VSTM

Business Wire

3 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

VSTM

MT Newswires

3 months ago

RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating

VSTM

Associated Press Finance

3 months ago

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

VSTM

Business Wire

3 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

VSTM

Business Wire

4 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

VSTM

MT Newswires

5 months ago

B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

VSTM

Business Wire

5 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

VSTM

Business Wire

5 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

VSTM

MT Newswires

6 months ago

Verastem Names Matthew E. Ros as COO

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

VSTM

Business Wire

6 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

VSTM

MT Newswires

6 months ago

Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

VSTM

Business Wire

6 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

VSTM

Business Wire

6 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

VSTM

Business Wire

6 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

6 months ago

RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk

VSTM

Zacks

6 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

VSTM

GuruFocus.com

6 months ago

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

VSTM

MT Newswires

6 months ago

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

VSTM

MT Newswires

6 months ago

Top Premarket Gainers

VSTM

MT Newswires

6 months ago

BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating

VSTM

MT Newswires

6 months ago

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

VSTM

Business Wire

6 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

VSTM

GlobeNewswire

6 months ago

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

VSTM

MT Newswires

6 months ago

Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

VSTM

Business Wire

6 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

VSTM

Business Wire

7 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

VSTM

Associated Press Finance

8 months ago

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

VSTM

Business Wire

8 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology submits NDA for ovarian cancer treatment

VSTM

Pharmaceutical Technology

8 months ago

Verastem Oncology submits NDA for ovarian cancer treatment

VSTM

MT Newswires

8 months ago

Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

VSTM

Business Wire

8 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

VSTM

Business Wire

8 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

VSTM

MT Newswires

8 months ago

Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

VSTM

Business Wire

8 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

VSTM

Business Wire

9 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

VSTM

Business Wire

9 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

9 months ago

Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

VSTM

Business Wire

10 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

VSTM

Business Wire

10 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

VSTM

Business Wire

10 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

VSTM

MT Newswires

a year ago

RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating

VSTM

Associated Press Finance

a year ago

Verastem: Q2 Earnings Snapshot

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

VSTM

Business Wire

a year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

VSTM

MT Newswires

a year ago

Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

VSTM

Business Wire

a year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

VSTM

MT Newswires

a year ago

B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating

VSTM

MT Newswires

a year ago

Top Premarket Decliners

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

VSTM

Business Wire

a year ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

VSTM

Business Wire

a year ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

VSTM

Zacks

a year ago

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor

VSTM

Clinical Trials Arena

a year ago

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor

VSTM

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

VSTM

MT Newswires

a year ago

Verastem Says First Patient Dosed in Phase 1/2 Solid Tumor Trial in China

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

VSTM

Business Wire

a year ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

VSTM

Business Wire

a year ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

a year ago

Truist Securities Adjusts Price Target on Verastem to $18 From $34, Notes Recent Stock Pull Back; Maintains Buy Rating

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

VSTM

Business Wire

a year ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

VSTM

MT Newswires

a year ago

RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier

VSTM

MT Newswires

a year ago

Top Midday Decliners

VSTM

Zacks

a year ago

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

VSTM

Benzinga

a year ago

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

VSTM

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Pre-Bell Friday

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

VSTM

Pharmaceutical Technology

a year ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

VSTM

Clinical Trials Arena

a year ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

VSTM

MT Newswires

a year ago

Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

VSTM

Business Wire

a year ago

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

VSTM

Business Wire

a year ago

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Latest Verastem Inc. (VSTM) News on July 1, 2025

Share on Social Networks: